Literature DB >> 20856735

Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy.

Arash Naeim1, Lyssa Friedman, Kimberly B Whitlock, David J Pasta, Eric P Elkin, Deborah P Lubeck, Hema N Viswanathan, John Glaspy.   

Abstract

Use of erythropoiesis-stimulating agents in the treatment of myelosuppresive chemotherapy-induced anemia has been shown to increase hemoglobin levels and reduce the need for transfusions in patients with cancer.

Entities:  

Year:  2009        PMID： 20856735      PMCID： PMC2790673          DOI： 10.1200/JOP.091011

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  15 in total

1.  Multidimensional independent predictors of cancer-related fatigue.

Authors:  Shirley S Hwang; Victor T Chang; Montse Rue; Basil Kasimis
Journal:  J Pain Symptom Manage       Date:  2003-07       Impact factor: 3.612

Review 2.  Fatigue in patients with advanced cancer: a review.

Authors:  E A Barnes; E Bruera
Journal:  Int J Gynecol Cancer       Date:  2002 Sep-Oct       Impact factor: 3.437

3.  The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.

Authors:  G P Browman; M N Levine; E A Mohide; R S Hayward; K I Pritchard; A Gafni; A Laupacis
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

Review 4.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  J Bohlius; J Wilson; J Seidenfeld; M Piper; G Schwarzer; J Sandercock; S Trelle; O Weingart; S Bayliss; S Brunskill; B Djulbegovic; C L Benett; S Langensiepen; C Hyde; E Engert
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

5.  Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials.

Authors:  J Seidenfeld; M Piper; C Flamm; V Hasselblad; J O Armitage; C L Bennett; M S Gordon; A E Lichtin; J L Wade; S Woolf; N Aronson
Journal:  J Natl Cancer Inst       Date:  2001-08-15       Impact factor: 13.506

6.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

7.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

Authors:  J Douglas Rizzo; Alan E Lichtin; Steven H Woolf; Jerome Seidenfeld; Charles L Bennett; David Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Stephanie J Lee; Carole B Miller; Mark U Rarick; David H Regan; George P Browman; Michael S Gordon
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

8.  Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Authors:  Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

Review 9.  Cancer-related fatigue: evolving concepts in evaluation and treatment.

Authors:  Roberto Stasi; Luca Abriani; Patrizia Beccaglia; Edmondo Terzoli; Sergio Amadori
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

10.  Fatigue in advanced cancer: a prospective controlled cross-sectional study.

Authors:  P Stone; J Hardy; K Broadley; A J Tookman; A Kurowska; R A'Hern
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640
View more
  1 in total

1.  Commentary: do guidelines influence physician practice behavior? The experience with erythropoiesis-stimulating agents.

Authors:  Marcus Neubauer; Roy A Beveridge; Michael Kolodziej
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.